Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Evidence- |
RCV000112503 | SCV000299453 | pathogenic | Breast-ovarian cancer, familial 1 | 2016-09-08 | reviewed by expert panel | curation | Variant allele predicted to encode a truncated non-functional protein. |
Invitae | RCV000048433 | SCV000076446 | pathogenic | Hereditary breast and ovarian cancer syndrome | 2016-01-01 | criteria provided, single submitter | clinical testing | This sequence change inserts 1 nucleotide in exon 6 of the BRCA1 mRNA (c.406dupA), causing a frameshift at codon 136. This creates a premature translational stop signal (p.Arg136Lysfs*6) and is expected to result in an absent or disrupted protein product. Truncating variants in BRCA1 are known to be pathogenic. This particular truncation has been reported in breast cancer affected individuals from a family with a strong history of breast and ovarian cancers (PMID: 10880552). This variant is also known as 525insA in the literature. ClinVar contains an entry for this variant (Variation ID: 55095). For these reasons, this variant has been classified as Pathogenic. |
Consortium of Investigators of Modifiers of BRCA1/2 |
RCV000112503 | SCV000325835 | pathogenic | Breast-ovarian cancer, familial 1 | 2015-10-02 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000484275 | SCV000568434 | pathogenic | not provided | 2016-01-08 | criteria provided, single submitter | clinical testing | This duplication of one nucleotide in BRCA1 is denoted c.406dupA at the cDNA level and p.Arg136LysfsX6 (R136KfsX6) at the protein level. This variant is also known as BRCA1 525insA using alternate nomenclature. The normal sequence, with the base that is duplicated in braces, is CAAA[A]GACT. The duplication causes a frameshift, which changes an Arginine to a Lysine at codon 136, and creates a premature stop codon at position 6 of the new reading frame. This variant is predicted to cause loss of normal protein function through either protein truncation or nonsense-mediated mRNA decay. BRCA1 c.406dupA has been observed in association with ovarian cancer (Werness 2000). We consider this variant to be pathogenic. |
Ambry Genetics | RCV000510018 | SCV000608214 | pathogenic | Hereditary cancer-predisposing syndrome | 2017-05-19 | criteria provided, single submitter | clinical testing | Lines of evidence used in support of classification: Alterations resulting in premature truncation (e.g.reading frame shift, nonsense) |
Quest Diagnostics Nichols Institute San Juan Capistrano | RCV000484275 | SCV000887683 | pathogenic | not provided | 2017-08-31 | criteria provided, single submitter | clinical testing | |
Breast Cancer Information Core |
RCV000112503 | SCV000145325 | pathogenic | Breast-ovarian cancer, familial 1 | 1998-11-23 | no assertion criteria provided | clinical testing |